|
Title
|
|
|
|
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP ( cyclophosphamide, doxorubicin, vincristine, and prednisone)like, ACVBP ( doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV ( cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000. In our sample, the proportion who received each of the three regimens was 78.4, 16.4, and 5.2%, respectively. Of those prescribed CHOP-like regimens, 15% received 80% average relative dose intensity (ARDI). In 210 patients treated with CHOP-21 (77% of the CHOP-like group), median survival was 7.08 years in those who received > 90% of the ARDI, significantly longer than in those who received <=; 90% of the ARDI (p= 0.002). Dose reductions and/or delays, mainly due to hematological toxicities, resulted in a reduction in treatment intensity. These data indicate that patient outcome is improved when the intensity of chemotherapy treatment is optimal. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Annals of hematology. - Berlin, 1991, currens
| |
|
Publication
|
|
|
|
Berlin
:
2008
| |
|
ISSN
|
|
|
|
0939-5555
[print]
1432-0584
[online]
| |
|
DOI
|
|
|
|
10.1007/S00277-007-0399-Y
| |
|
Volume/pages
|
|
|
|
87
:4
(2008)
, p. 277-283
| |
|
ISI
|
|
|
|
000254176400004
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|